Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized placebo-controlled study of sotatercept in Cpc-PH due to HFpEF
2021-003020-32Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension due to left heart disease (PH-LHD) comparing Sotatercept with Placebo (2 arms). Started Oct 2021; status: active.
02
Drugs
sotatercept
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)
Beyond the preview
Go deeper on 2021-003020-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003020-32.